Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Research And Development Expenses	$ 5,451,287	$ 3,279,323	$ 10,356,965	$ 6,869,376
Terms of license Agreement			Belgian Volition received an upfront payment of $10.0 million in 2022, and is eligible to receive further milestone payments of (i) $6.5 million upon the first commercial sale by or on behalf of Heska of a POC screening test for Canine Lymphoma & HSA, (ii) $6.5 million upon the first commercial sale by or on behalf of Heska of a POC monitoring test for the same conditions, and (iii) $5.0 million upon the first commercial sale by or on behalf of Heska of a screening or monitoring test for lymphoma in felines
Deferred Revenue	10,000,000.0		$ 10,000,000.0
Cash and cash equivalents	19,743,274		19,743,274		$ 10,867,050
Accounts receivable	196,487		196,487		$ 72,609
Cash and cash equivalent [Member]
Cash and cash equivalents	$ 19,700,000		19,700,000
Research And Development Expenses [Member]
Research And Development Expenses			$ 10,400,000	$ 6,900,000
Warrants And Options [Member]
Potentially Dilutive Securities Excluded From The Computation Of Eps	7,795,320		7,795,320